Augustine’s approach focuses on inhibiting the cytosolic histone deacetylase 6 (HDAC6) enzyme, which plays a key role in neurodegeneration and aging-related cellular processes. The company’s ...

Neoadjuvant chemotherapy (NACT) use in triple-negative breast cancer (TNBC) increased from 19.1% to 56.4% between 2010 and 2021, with pathologic complete response (pCR) rates rising from 19.6% to ...

Eight months after announcing the $18.5 million first tranche of its series A, Augustine Therapeutics has closed the oversubscribed round at $85 million and is now ready to begin clinical development ...

The spending has enabled the 81-year-old business to establish fully integrated capabilities spanning the entire drug lifecycle and world-leading expertise in HDAC6 biology. CKD is developing non ...